{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:08:10Z","timestamp":1762160890510,"version":"3.38.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[1995,9]]},"abstract":"<jats:p><jats:italic>Background and Purpose<\/jats:italic>Excessive calcium entry into depolarized neurons contributes significantly to cerebral tissue damage after ischemia. We evaluated the ability of a novel neuronal calcium channel blocker, SB 201823-A, to block central neuronal calcium influx in vitro and to reduce ischemic injury in two rodent models of focal stroke.<\/jats:p><jats:p><jats:italic>Methods<\/jats:italic>Patch-clamp electrophysiology and intracellular Ca<jats:sup>2+<\/jats:sup>imaging in rat hippocampal and cerebellar neurons were used to determine effects on neuronal calcium channel activity. Middle cerebral artery occlusion was performed in Fisher 344 rats and CD-1 mice to determine the effects on rodent focal ischemic injury and neurological deficits. Cardiovascular monitoring in conscious rats was conducted to determine cardiovascular liabilities of the compound.<\/jats:p><jats:p><jats:italic>Results<\/jats:italic>In cultured rat hippocampal cells, calcium current measured at plateau was reduced by 36\u00b18% and 89\u00b14% after 5 and 20 \u03bcmol\/L SB 201823-A, respectively. In cerebellar granule cells in culture, pretreatment with 2.5 \u03bcmol\/L SB 201823-A totally prevented initial calcium influx and reduced later calcium influx by 50\u00b12.5% after<jats:italic>N<\/jats:italic>-methyl-<jats:sc>d<\/jats:sc>-aspartate\/glycine stimulation (<jats:italic>P<\/jats:italic>&lt;.01). KCl depolarization\u2013induced calcium influx also was reduced by more than 95%. In rats, a single treatment with 10 mg\/kg IV SB 201823-A beginning 30 minutes after focal ischemia decreased (<jats:italic>P<\/jats:italic>&lt;.05) hemispheric infarct by 30.4% and infarct volume by 29.3% and reduced (<jats:italic>P<\/jats:italic>&lt;.05) forelimb deficits by 47.8% and hindlimb deficits by 36.3%. In mice, treatments with 10 mg\/kg IP SB 201823-A beginning 30 minutes after focal ischemia significantly reduced infarct volume by 41.5% (<jats:italic>P<\/jats:italic>&lt;.01). No blood pressure effects were observed with the therapeutic dose of the compound.<\/jats:p><jats:p><jats:italic>Conclusions<\/jats:italic>These results indicate that the new neuronal calcium channel blocker SB 201823-A can block stimulated calcium influx into central neurons and can provide neuroprotection in two models of focal cerebral ischemia without affecting blood pressure. Data from several different studies now indicate that the neuronal calcium channel antagonists are a promising therapy for the postischemic treatment of stroke.<\/jats:p>","DOI":"10.1161\/01.str.26.9.1683","type":"journal-article","created":{"date-parts":[[2011,6,17]],"date-time":"2011-06-17T20:08:03Z","timestamp":1308341283000},"page":"1683-1690","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["SB 201823-A Antagonizes Calcium Currents in Central Neurons and Reduces the Effects of Focal Ischemia in Rats and Mice"],"prefix":"10.1161","volume":"26","author":[{"given":"F. C.","family":"Barone","sequence":"first","affiliation":[{"name":"From SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (F.C.B., P.G.L., W.J.P., G.F.), and New Frontiers Science Park, Harlow, UK (K.A.Al-B., C.D.B., D.C.H., M.H.H., S.J.B., A.J.H.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. G.","family":"Lysko","sequence":"additional","affiliation":[{"name":"From SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (F.C.B., P.G.L., W.J.P., G.F.), and New Frontiers Science Park, Harlow, UK (K.A.Al-B., C.D.B., D.C.H., M.H.H., S.J.B., A.J.H.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. J.","family":"Price","sequence":"additional","affiliation":[{"name":"From SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (F.C.B., P.G.L., W.J.P., G.F.), and New Frontiers Science Park, Harlow, UK (K.A.Al-B., C.D.B., D.C.H., M.H.H., S.J.B., A.J.H.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Feuerstein","sequence":"additional","affiliation":[{"name":"From SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (F.C.B., P.G.L., W.J.P., G.F.), and New Frontiers Science Park, Harlow, UK (K.A.Al-B., C.D.B., D.C.H., M.H.H., S.J.B., A.J.H.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. A.","family":"Al-Baracanji","sequence":"additional","affiliation":[{"name":"From SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (F.C.B., P.G.L., W.J.P., G.F.), and New Frontiers Science Park, Harlow, UK (K.A.Al-B., C.D.B., D.C.H., M.H.H., S.J.B., A.J.H.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. D.","family":"Benham","sequence":"additional","affiliation":[{"name":"From SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (F.C.B., P.G.L., W.J.P., G.F.), and New Frontiers Science Park, Harlow, UK (K.A.Al-B., C.D.B., D.C.H., M.H.H., S.J.B., A.J.H.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. C.","family":"Harrison","sequence":"additional","affiliation":[{"name":"From SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (F.C.B., P.G.L., W.J.P., G.F.), and New Frontiers Science Park, Harlow, UK (K.A.Al-B., C.D.B., D.C.H., M.H.H., S.J.B., A.J.H.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. H.","family":"Harries","sequence":"additional","affiliation":[{"name":"From SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (F.C.B., P.G.L., W.J.P., G.F.), and New Frontiers Science Park, Harlow, UK (K.A.Al-B., C.D.B., D.C.H., M.H.H., S.J.B., A.J.H.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. J.","family":"Bailey","sequence":"additional","affiliation":[{"name":"From SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (F.C.B., P.G.L., W.J.P., G.F.), and New Frontiers Science Park, Harlow, UK (K.A.Al-B., C.D.B., D.C.H., M.H.H., S.J.B., A.J.H.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"Hunter","sequence":"additional","affiliation":[{"name":"From SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (F.C.B., P.G.L., W.J.P., G.F.), and New Frontiers Science Park, Harlow, UK (K.A.Al-B., C.D.B., D.C.H., M.H.H., S.J.B., A.J.H.)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1988.tb33410.x"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1989.20"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1984.tb05396.x"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1988.tb01111.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(90)90799-F"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(88)90200-7"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410190202"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.386513"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Allain H Decombe R Saiag B Benme-Ferrer Guez D. Mechanistic basis for the development of antiischemic drugs. Cerebrovasc Dis. 1991;(suppl 1):83-92.","DOI":"10.1159\/000108902"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410250412"},{"key":"e_1_3_2_11_2","first-page":"571","volume":"247","year":"1990","unstructured":"Sheardown MJ, Nielsen EO, Hansen AJ, Jacobsen P, Honore T. 2,3 Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quiinoxaline: a neuroprotectant for cerebral ischemia. Stroke. 1990;247:571-574.","journal-title":"Stroke"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1994.32"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410240411"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Feuerstein G Hunter J Barone FC. Calcium channel blockers and neuroprotection. In: Marangos JP Lal H eds. Emerging Strategies in Neuroprotection. Boston Mass: Birkhauser; 1992:129-150.","DOI":"10.1007\/978-1-4684-6796-3_8"},{"key":"e_1_3_2_15_2","first-page":"87","volume":"707","year":"1994","unstructured":"Mori Y, Niidome T, Fujita Y, Mynlieff M, Dirksen RT, Beam KG, Iwabe N, Miyata T, Furutama D, Furuichi T, Mikoshiba K. Molecular diversity of voltage-dependent calcium channel. Ann N Y Acad Sci. 1994;707:87-108.","journal-title":"Ann N Y Acad Sci"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)45955-8"},{"key":"e_1_3_2_17_2","first-page":"349","volume":"23","year":"1991","unstructured":"Tsien RW, Ellinor PT, Hone WA. Molecular diversity of voltage-dependent Ca2+ channels. Trends Pharmacol Sci. 1991;23:349-354.","journal-title":"Trends Pharmacol Sci"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-4388(92)90111-W"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2432656"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198937050-00004"},{"key":"e_1_3_2_21_2","first-page":"1253","volume":"18","year":"1992","unstructured":"Valentino K, Bowersox S, Smith ML, Siesj\u00f6 BK, Singh T, Gadbois T, Justice A, Ramachandran J, Hoffman BB. Delayed treatment with a selective neuronal calcium channel antagonist protects against neuronal death after global cerebral ischaemia. Soc Neurosci Abstr. 1992;18:1253. Abstract.","journal-title":"Soc Neurosci Abstr"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0026-895X(25)09500-8","volume":"38","year":"1990","unstructured":"Scott RH, Dolphin AC, Bindokas VP, Adams ME. Inhibition of neuronal Ca2+ channel currents by the funnel web spider toxin \u03d6-Aga-IA. Mol Pharmacol. 1990;38:711-718.","journal-title":"Mol Pharmacol"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(94)90501-0"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(93)90019-Y"},{"key":"e_1_3_2_25_2","unstructured":"Brown TH Cooper DG. International Patent Application WO92\/02502. 1992."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(88)90765-2"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(89)90773-7"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(89)90774-9"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1989.tb12512.x"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(92)90798-C"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)90653-D"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.23.9.1519289"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-7634(05)80182-4"},{"key":"e_1_3_2_34_2","first-page":"472","volume":"20","year":"1989","unstructured":"Bederson JB, Pitts LH, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurological examination. Stroke. 1989;20:472-476.","journal-title":"Stroke"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.17.6.1304"},{"key":"e_1_3_2_36_2","unstructured":"Seigal S. Nonparametric Statistics for the Behavioral Sciences. New York NY: McGraw Hill Book Co; 1956."},{"key":"e_1_3_2_37_2","unstructured":"Winer BJ. Statistical Principles in Experimental Design. New York NY: McGraw-Hill Book Co; 1971."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(92)90045-A"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.11-04-01049.1991"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(91)90362-4"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(92)90223-Z"},{"key":"e_1_3_2_42_2","unstructured":"Sheardown MJ Hansen AJ Petsen V Birn P Judge M Jakobsen P. The neuroprotective effect of NNC 09-0026 a new calcium channel blocker in global ischemia. J Cereb Blood Flow Metab. 1993;13(suppl 1):S662. Abstract."}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.STR.26.9.1683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T08:12:20Z","timestamp":1741248740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.STR.26.9.1683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1995,9]]}},"alternative-id":["10.1161\/01.STR.26.9.1683"],"URL":"https:\/\/doi.org\/10.1161\/01.str.26.9.1683","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"type":"print","value":"0039-2499"},{"type":"electronic","value":"1524-4628"}],"subject":[],"published":{"date-parts":[[1995,9]]},"assertion":[{"value":"1994-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1995-05-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1995-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}